Oncolytics Announces Up To $80M At-The-Market Facility
Oncolytics Announces Up To $80M At-The-Market Facility
SAN DIEGO, Calif. and CALGARY, AB, March 5, 2021 /CNW/ ---- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into an at-the-market (ATM) equity offering sales agreement with Canaccord Genuity LLC. The ATM allows the Company, at its sole discretion, to issue common shares from treasury, at prevailing market prices, with an aggregate gross sales amount of up to US$80 million. The company has no obligation to sell any shares pursuant to the ATM. The ATM provides Oncolytics the option to efficiently tap into the financial markets as needed to support ongoing business development activities and clinical trials, while bolstering management's ability to negotiate potential business development agreements from a position of financial strength.
加利福尼亞州聖迭戈和阿肯色州卡爾加里，2021年3月5日/CNW/Oncolytics Biotech®Inc.(納斯達克：Oncy)(多倫多證券交易所：ONC)，目前正在開發的Pelareorep是一種靜脈注射的免疫溶瘤病毒，今天宣佈它已經與Canaccel Genuity LLC簽訂了一項在市場上(ATM)股權發行的銷售協議。自動取款機允許公司自行決定以當時的市場價格從庫房發行普通股，總銷售額最高可達8000萬美元。根據自動取款機，該公司沒有義務出售任何股份。自動取款機為Oncolytics公司提供了根據需要有效地進入金融市場的選擇，以支持正在進行的業務開發活動和臨牀試驗，同時加強管理層從財務實力的立場談判潛在業務開發協議的能力。
In connection with the ATM, Oncolytics has filed a Prospectus Supplement with the Alberta Securities Commission and with the United States Securities and Exchange Commission, which supplements Oncolytics' Canadian short form base shelf prospectus dated June 12, 2020, and Oncolytics' shelf registration statement on Form F-10 declared effective on June 15, 2020 by the United States Securities and Exchange Commission. Sales of the ATM offering will only be conducted in the United States through NASDAQ or another exchange at market prices. No sales will be conducted in Canada or through the Toronto Stock Exchange.
關於自動取款機，Oncolytics公司已經向艾伯塔省證券委員會和美國證券交易委員會提交了一份説明書補充文件，補充了Oncolytics公司於2020年6月12日發佈的加拿大短格式基礎貨架招股説明書和美國證券交易委員會宣佈於2020年6月15日生效的Oncolytics公司F-10表格的貨架登記聲明。自動櫃員機產品的銷售將僅在美國通過納斯達克或另一家交易所以市場價格進行。不會在加拿大或通過多倫多證券交易所進行銷售。
A copy of the Prospectus Supplement is available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov or may be obtained upon request to Oncolytics' Investor Relations Department using the contact information set out below. Before you invest, you should read the Prospectus Supplement and accompanying base shelf prospectus and the other documents the Company has filed with the SEC for more complete information about the Company and the ATM offering. Alternatively, a copy of the Prospectus Supplement and accompanying base shelf prospectus are available upon request by contacting Canaccord Genuity LLC Attention: Syndicate Department, 99 High Street, Suite 1200, Boston, MA 02110, Attn: Equity Syndicate Department, by telephone at (617) 371-3900 or by e-mail at prospectus@cgf.com.
招股説明書補編的副本可在SEDAR上查閲，網址為Www.sedar.com和埃德加在Www.sec.gov或者可以使用下面列出的聯繫信息向Oncolytics的投資者關係部提出要求。在您投資之前，您應該閲讀招股説明書附錄和隨附的基本架子招股説明書，以及公司提交給證券交易委員會的其他文件，以獲得有關公司和自動取款機產品的更完整信息。或者，如有要求，可聯繫Canaccel Genuity有限責任公司索取招股説明書副刊和基礎架子招股説明書。聯繫地址：Syndicate Department，99 High Street，Suite1200，Boston，MA 02110，Attn：Equity Syndicate Department，電話：(617371-3900)，或發送電子郵件至郵箱：prospectus@cgf.com.
譯文內容由第三人軟體翻譯。